Dopamine receptor agonists mediate neuroprotection in malonate-induced striatal lesion in the rat

Experimental Neurology

Volumn 178, Issue 2, 2002, Pages 301-305

  Armentero, Marie Thérèse ^a   Fancellu, Roberto ^a,b   Nappi, Giuseppe ^a,c   Blandini, Fabio ^a,d  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Lab Funct Neuro Neu Inst C M   (Italy)

Author keywords

Apomorphine; Basal ganglia; Cytochrome oxidase; Quinpirole; SKF 38393; Striatum

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; MALONIC ACID; MITOCHONDRIAL ENZYME; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL GANGLION; BRAIN INJURY; CORPUS STRIATUM; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0036935103     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8033     Document Type: Article

References (39)

1. Ariano, M. 1988. Striatal D1 dopamine receptor distribution following chemical lesion of the nigrostriatal pathway. Brain Res. 443: 204-214.
2. Beal, M. F., E. Brouillet, B. Jenkins, R. Henshaw, B. Rosen, and B. T. Hyman. 1993. Age-dependent striatal lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem. 61: 1147-1150.
3. Bristow, L. J., G. P. Cook, S. Patel, N. Curtis, I. Mawer, and Kulagowski. 1998. Discriminative stimulus properties of the putative dopamine D3 receptor agonist, (+)-PD 128907: Role of presynaptic dopamine D2 autoreceptors. Neuropharmacology 37: 793-802.
4. Calabresi, P., A. Pisani, D. Centonze, and G. Bernardi. 1997. Synaptic plasticity and physiological interactions between dopamine and glutamate in the striatum. Neurosci. Behav. Rev. 21: 519-523.
5. Castro, N. G., M. C. F. de Mello, F. G. de Mello, and Y. Aracava. 1999. Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF-38393. Br. J. Pharmacol. 126: 1847-1855.
6. Divac, I., J. Mojsilovic-Petrovic, M. O. Lopez-Figueroa, B. Petrovic-Minic, and M. Moller. 1995. Improved contrast in histochemical detection for cytochrome oxidase: Metallic ions protocol. J. Neurosci. Methods 56: 105-113.
7. Ferger, B., O. Eberhardt, P. Teismann, C. de Groote, and J. B. Schulz. 1999. Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J. Neurochem. 73: 1329-1332.
8. Filloux, F., and J. J. Townsend. 1993. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp. Neurol. 119: 79-88.
9. Fornai, F., G. Battaglia, M. Gesi, F. Orzi, F. Nicoletti, and S. Ruggieri. 2001. Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage. Brain Res. 898: 27-35.
10. Gassen, M., Y. Glinka, B. Pinchasi, and M. B. H. Youdim. 1996. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308: 219-225.
11. Gerfen, C., T. Engber, L. Mahan, Z. Susel, T. Chase, F. Monsma, and D. Sibley. 1990. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250: 1429-1432.
12. Greene, J., and J. Greenamyre. 1995. Exacerbation of NMDA, AMPA, and L-glutamate excitotoxicity by the succinate dehydrogenase inhibitor malonate. J. Neurosci. 64: 2332-2338.
13. Greene, J., and J. Greenamyre. 1996. Manipulation of membrane potential modulates malonate-induced striatal excitotoxicity in vivo. J. Neurochem. 66: 637-643.
14. Greene, J., R. H. P. Porter, R. Eller, and J. Greenamyre. 1993. Inhibition of succinate dehydrogenase by malonic acid produces an "excitotoxic" lesion in rat striatum. J. Neurochem. 61: 1151-1154.
15. Greene, J., R. H. P. Porter, and J. Greenamyre. 1996. ARL-15896, a novel N-methyl-D-aspartate receptor ion channel antagonist: Neuroprotection against mitochondrial metabolic toxicity and regional pharmacology. Exp. Neurol. 137: 66-72.
16. Hastings, T. G., D. A. Lewis, and M. J. Zigmond. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93: 1956-1961.
17. Iida, M., I. Miyazaki, K. Tanaka, H. Kabuto, and E. Iwata-Ichikawa. 1999. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res. 838: 51-59.
18. Lindgren, N., Z. Q. Xu, M. Herrera-Marschitz, J. Haycock, J. Hokfelt, and G. Fisone. 2001. Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum. Eur. J. Neurosci. 13: 773-780.
19. Mao, A., K. H. Freeman, and R. J. Tallarida. 1996. Transient loss of dopamine autoreceptor control in the presence of highly potent dopamine agonists. Life Sci. 59: 317-324.
20. McLaughlin, B. A., D. Nelson, M. Erecinska, and M.-F. Chesselet. 1998. Toxicity of dopamine to striatal neurons in vitro and potentiation of cell death by mitochondrial inhibitor. J. Neurochem. 70: 2406-2415.
21. Mizuno, B. E., H. Mori, and T. Kondo. 1994. Potential neuroprotective therapy in Parkinson's disease. CNS Drugs 1: 45-56.
22. Moy, L. Y., G. D. Zeevalk, and P. K. Sonsalla. 2000. Role of dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J. Neurochem. 74: 1656-1665.
23. Muralikrishnan, D., and M. Ebadi. 2001. SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. 892: 241-247.
24. Nisenbaum, E. S., P. G. Mermelstein, C. J. Wilson, and D. J. Smeier. 1998. Selective blockade of a slowly inactivating potassium current in striatal neurons by (+/-) 6-chloro-APB hydrobromide (SKF82958). Synapse 29: 213-224.
25. Nishibayashi, A., M. Asanuma, M. Kohno, M. Gomez-Vargas, and N. Ogawa. 1996. Scavenging effect of dopamine agonists on nitric oxide radicals. J. Neurochem. 67: 2208-2211.
26. Obuchowicz, E. 1999. Differential behavioral effect of quinpi-role in neuroleptic-pretreated rats: Role of alpha (1)-adrenoceptor. Eur. J. Pharmacol. 384: 101-109.
27. Olanow, W., P. Jenner, and D. Brook. 1998. Dopamine agonists and neuroprotection in Parkinson's disease. Ann. Neurol. 44: S167-S174.
28. Sawada, H., M. T. K. Ibi, M. Urushitani, A. Akaike, J. Kimura, and S. Shimohama. 1998. Dopamine D2-type agonist protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44: 110-119.
29. Schapira, A. H. V. 2002. Neuroprotection and dopamine agonists. Neurology 58: S9-S18.
30. Spencer, J. P., A. Jenner, J. Butler, O. I. Aruoma, D. T. Dexter, P. Jenner, and B. Halliwell. 1996. Evaluation of the pro-oxidant actions of L-DOPA and dopamine in vitro: Implications for Parkinson's disease. Free Radic. Res. 24: 95-105.
31. Tomiyama, K., N. Koshikawa, K. Funada, K. Oka, and M. Kobayashi. 1995. In vivo microdialysis evidence for transient dopamine release by benzazepines in rat striatum. J. Neurochem. 65: 2790-2795.
32. Vallar, L., and J. Meldolesi. 1989. Mechanism of signal transduction at the dopamine D2 receptor. Trends Pharmacol. Sci. 10: 74-77.
33. Walters, D. E., and S. G. Howard. 1990. The D1 agonist SKF 38393 increases dopamine release in the developing rat striatum. Eur. J. Pharmacol. 184: 257-264.
34. Xia, X. G., Schmidt, P. Teismann, B. Ferger, and B. Schulz. 2001. Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. J. Neurochem. 79: 63-70.
35. Yamamoto, B. K., and M. A. Cooperman. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14: 4159-4166.
36. Yamamoto, B. K., and S. Davy. 1992. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58: 1736-1742.
37. Zackheim, J. A., and E. D. Abercrombie. 2001. Decreased striatal dopamine efflux after intrastriatal aplication of benzazepine-class D1 agonists is not mediated via dopamine receptor. Brain Res. Bull. 54: 603-607.
38. Zeevalk, G. D., L. P. Bernard, D. S. Albers, O. Mirochnitchenko, W. J. Nicklas, and P. K. Sonsalla. 1997a. Energy stress-induced dopamine loss in glutathione peroxidase-overexpressing transgenic mice and in glutathione-depleted mesencephalic cultures. J. Neurochem. 68: 426-429.
39. Zeevalk, G. D., L. Manzino, J. Hoppe, and P. K. Sonsalla. 1997b. In vivo vulnerability of dopamine neurons to inhibition of metabolism. J. Pharmacol. 320: 111-119.